Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon, Ltd.

http://www.biocon.com/

Latest From Biocon, Ltd.

India Q2 Preview: Glenmark, Cipla Emerge Stronger

With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.

Commercial Coronavirus COVID-19

Does The Pandemic Present Opportunities To Rethink Regulatory Approaches?

Biocon chair believes new perspectives on regulatory science and processes emerging from the US's "Warp Speed" efforts to accelerate COVID-19 vaccines have potential for wider application, although Regeneron's president urges caution around relying only on small studies to advance repurposed drugs.

Regulation Coronavirus COVID-19

No EUA For COVID-19 Vaccines Prior To Trials Completion, Says India

The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate

Policy & Regulation Research and Development Strategies

No EUA For COVID-19 Vaccines Prior To Trials Completion, Says India

The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Biocon Sdn Bhd.
    • Biocon Limited
    • Biocon Biologics India Ltd
    • Bicara Therapeutics
UsernamePublicRestriction

Register